|Bid||162.18 x 0|
|Ask||162.86 x 0|
|Day's Range||160.51 - 160.51|
|52 Week Range||133.26 - 172.26|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Does the share price for Thermo Fisher Scientific Inc (NYSE:TMO) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. IfRead More...
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Shares of Thermo Fisher Scientific Inc. (NYSE: TMO ) came under heavy selling pressure last Friday, which continued into Monday's trading session amid ongoing concerns that Amazon.com, Inc. (NASDAQ: AMZN ...
Thermo Fisher Scientific and Boston Scientific, the state’s largest medical device and scientific equipment companies, say they are still grappling with the aftermath of Hurricane Maria, which knocked out power on most of the island. Like many other device firms nationally, Waltham-based Thermo Fisher (TMO) and Marlborough-based Boston Scientific (BSX) each have facilities in Puerto Rico due in part to the U.S. territory’s favorable corporate tax climate. With 75 percent of the island still without power and 25 percent without water as of Wednesday — more than a month after Maria made landfall — the industry has been working closely with the FDA to get facilities back online in an effort to prevent shortages of critical products.
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, on Wednesday reported a higher-than-expected quarterly profit, fueled by sales growth in all of its units and contributions ...
The Waltham, Massachusetts-based company said it had profit of $1.34 per share. Earnings, adjusted for one-time gains and costs, came to $2.31 per share. The results topped Wall Street expectations. The ...
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting TMO. Over the last one-month, outflows of investor capital in ETFs holding TMO totaled $38.27 billion.
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.